Results 201 to 210 of about 14,894 (236)
Some of the next articles are maybe not open access.
Applied Radiation and Isotopes, 1998
Previous studies report that deferoxamine (DFO) binds metallic ions such as Fe3+, In3+ and Ga3+ with very high affinity. This property of DFO has been utilized to label DFO-coupled compounds with radiometals such as 67Ga and 111In. We have studied the effect of low DFO concentrations and of different incubation conditions on the stability of the 67Ga ...
Corradina Caracò +2 more
openaire +3 more sources
Previous studies report that deferoxamine (DFO) binds metallic ions such as Fe3+, In3+ and Ga3+ with very high affinity. This property of DFO has been utilized to label DFO-coupled compounds with radiometals such as 67Ga and 111In. We have studied the effect of low DFO concentrations and of different incubation conditions on the stability of the 67Ga ...
Corradina Caracò +2 more
openaire +3 more sources
Effects of Deferoxamine on Fat Graft Survival [PDF]
Facial Plastic Surgery, 2016 The most important problem in fat transplantation is the unpredictable rates of resorption. Deferoxamine (DFO) is an iron-chelating agent with many useful functions including stimulating angiogenesis and antioxidant nature. The purpose of the study is to evaluate the effects of DFO on fat graft viability in rat model.
Deniz Filinte +4 more
openaire +2 more sources
MULTIMODAL IMAGING IN DEFEROXAMINE RETINOPATHY
Retina, 2014To describe macular lesions in patients with deferoxamine (DFO) retinopathy, and to follow their clinical course using multimodal imaging.The authors retrospectively reviewed charts and multimodal imaging of 20 patients with β-thalassemia diagnosed with DFO retinopathy (40 eyes) after a minimum of 10 years of DFO treatment.
F. Viola +6 more
openaire +3 more sources
Deferoxamine: Effects on intravitreal iron
Experimental Eye Research, 1976Abstract Deferoxamine has been shown to increase urinary excretion of intraocular iron in rabbits. However, the maximum excretion obtained was less than 2 μg per day. Solid foreign bodies were removed at less than one part per million per day despite rapid dissolution with siderosis formation.
openaire +3 more sources
Iron and Deferoxamine in Lymphocyte Blastogenesis
Journal of Immunopharmacology, 1980Murine lymphocytes in tissue culture accumulate 59Fe during the blastogenic process. The accumulation of iron is related to the time of maximal activity of DNA synthesis. A chelator of iron, deferoxamine, inhibits blastogenesis with 50% inhibitory concentration of 5 microM.
J. J. Lipsky, Paul S. Lietman
openaire +3 more sources
Evaluation of Deferoxamine In Iron Overload
Archives of Internal Medicine, 1964One of the distinctive features of human iron metabolism is the body's limited ability to excrete iron. When iron accumulates in great excess, associated tissue damage may appear. The consensus today is that removal of the excess iron is desirable.1,2Removal of the vast accumulations of iron in patients with idiopathic hemochromatosis by repeated ...
Elmer B. Brown, Yun-Fei Hwang
openaire +3 more sources
Journal of Cardiovascular Pharmacology, 1990
Deferoxamine (DFX) is a specific Fe3+ chelator that is used to manage iron overload, and is being evaluated as an agent to reduce ischemic organ damage that involves iron-mediated OH formation. However, high intravascular doses cause significant hemodynamic changes that may limit or counteract beneficial effects. We used conscious, closed-chest dogs to
Kim P. Gallagher +5 more
openaire +3 more sources
Deferoxamine (DFX) is a specific Fe3+ chelator that is used to manage iron overload, and is being evaluated as an agent to reduce ischemic organ damage that involves iron-mediated OH formation. However, high intravascular doses cause significant hemodynamic changes that may limit or counteract beneficial effects. We used conscious, closed-chest dogs to
Kim P. Gallagher +5 more
openaire +3 more sources
Synthesis and solution properties of deferoxamine amides
Journal of Pharmaceutical Sciences, 2000The poor membrane permeability and oral bioavailability of the iron chelating agent deferoxamine (DFO) mesylate result from the low octanol/water partition coefficient and high aqueous solubility. With the ultimate aim to improve biomembrane permeability while retaining the iron-binding ability of DFO, a series of more lipophilic amides were prepared ...
Jonathan L. Vennerstrom +3 more
openaire +3 more sources
Journal of Infectious Diseases, 1995
The iron chelator deferoxamine (DFO) B enhances virulence of Yersinia enterocolitica and modulates cellular immune responses. Since cytokines mediate effector mechanisms in resolution of yersiniae from infected tissues, the impact of DFO B and DFO G1 on cytokine production by murine bone marrow macrophages (BMM) was investigated.
Iogo B. Autenrieth +3 more
openaire +3 more sources
The iron chelator deferoxamine (DFO) B enhances virulence of Yersinia enterocolitica and modulates cellular immune responses. Since cytokines mediate effector mechanisms in resolution of yersiniae from infected tissues, the impact of DFO B and DFO G1 on cytokine production by murine bone marrow macrophages (BMM) was investigated.
Iogo B. Autenrieth +3 more
openaire +3 more sources
Deferoxamine therapy for intracerebral hemorrhage
2009Intracerebral hemorrhage (ICH) is a subtype of stroke with very high mortality. Experiments have indicated that clot lysis and iron play an important role in ICH-induced brain injury. Iron overload occurs in the brain after ICH in rats. Intracerebral infusion of iron causes brain edema and neuronal death.
Ya Hua +3 more
openaire +2 more sources